JP2016508123A - 萎縮治療のための又は細胞増殖を増加させるための医薬 - Google Patents

萎縮治療のための又は細胞増殖を増加させるための医薬 Download PDF

Info

Publication number
JP2016508123A
JP2016508123A JP2015547046A JP2015547046A JP2016508123A JP 2016508123 A JP2016508123 A JP 2016508123A JP 2015547046 A JP2015547046 A JP 2015547046A JP 2015547046 A JP2015547046 A JP 2015547046A JP 2016508123 A JP2016508123 A JP 2016508123A
Authority
JP
Japan
Prior art keywords
cells
serf2
cell
nucleic acid
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508123A5 (enExample
Inventor
ルドルフ　ベルガー
ベルガー ルドルフ
Original Assignee
ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト
ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト, ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト filed Critical ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト
Publication of JP2016508123A publication Critical patent/JP2016508123A/ja
Publication of JP2016508123A5 publication Critical patent/JP2016508123A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015547046A 2012-12-14 2013-12-13 萎縮治療のための又は細胞増殖を増加させるための医薬 Pending JP2016508123A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197192.3A EP2742935A1 (en) 2012-12-14 2012-12-14 SERF2 for the treatment of atrophy and for increasing cell growth
EP12197192.3 2012-12-14
PCT/EP2013/076547 WO2014090991A1 (en) 2012-12-14 2013-12-13 Medicament for atrophy treatment or increasing cell growth

Publications (2)

Publication Number Publication Date
JP2016508123A true JP2016508123A (ja) 2016-03-17
JP2016508123A5 JP2016508123A5 (enExample) 2017-01-19

Family

ID=47355920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015547046A Pending JP2016508123A (ja) 2012-12-14 2013-12-13 萎縮治療のための又は細胞増殖を増加させるための医薬

Country Status (7)

Country Link
US (2) US9637529B2 (enExample)
EP (2) EP2742935A1 (enExample)
JP (1) JP2016508123A (enExample)
CN (1) CN105163726A (enExample)
AU (1) AU2013357283A1 (enExample)
CA (1) CA2895131A1 (enExample)
WO (1) WO2014090991A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3170888A1 (en) 2008-05-23 2017-05-24 Siwa Corporation Methods and compositions for facilitating regeneration
BR112017005517A2 (pt) 2014-09-19 2017-12-05 Siwa Corp anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
MX2018009988A (es) 2016-02-19 2018-12-17 Siwa Corp Metodo y composicion para tratar el cancer, destruir las celulas cancerosas metastasicas y evitar la metastasis del cancer usando anticuerpo para productos finales de glicacion avanzada (age).
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
US20200009198A1 (en) * 2016-11-30 2020-01-09 Paean Biotechnology Inc. Pharmaceutical compostion containing mitochondria
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN113337460A (zh) * 2021-06-10 2021-09-03 呼和浩特职业学院 一种绵羊骨骼肌卫星细胞的高效分离和纯化方法
CN118108828B (zh) * 2022-11-29 2025-10-28 上海众启生物科技有限公司 含有serf2的蛋白抗原组合及其应用
CN117538545B (zh) * 2024-01-09 2024-07-05 上海众启生物科技有限公司 一种用于阿尔茨海默症检测的蛋白抗原组合及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN HAM, T. J. ET AL.: ""Identification of MOAG-4/SERF as a Regulator of Age-Related Proteotoxicity"", CELL, vol. 142, no. 4, JPN6017037385, 20 August 2010 (2010-08-20), pages 601 - 612, ISSN: 0003651247 *

Also Published As

Publication number Publication date
AU2013357283A1 (en) 2015-07-09
EP2931264A1 (en) 2015-10-21
WO2014090991A1 (en) 2014-06-19
US20170253641A1 (en) 2017-09-07
US9637529B2 (en) 2017-05-02
US20150307568A1 (en) 2015-10-29
CN105163726A (zh) 2015-12-16
CA2895131A1 (en) 2014-06-19
EP2742935A1 (en) 2014-06-18

Similar Documents

Publication Publication Date Title
JP2016508123A (ja) 萎縮治療のための又は細胞増殖を増加させるための医薬
Fernandez et al. Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype
Wang et al. Slit3 secreted from M2-like macrophages increases sympathetic activity and thermogenesis in adipose tissue
Bagchi et al. The transcription factor scleraxis is a critical regulator of cardiac fibroblast phenotype
JP7113430B2 (ja) 生体組織損傷の修復剤および当該修復剤の製造方法
Berry et al. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/-mouse model for Duchenne muscular dystrophy
JP5122278B2 (ja) 眼細胞生存の促進におけるラクリチンの使用
Geetha-Loganathan et al. Avian facial morphogenesis is regulated by c-Jun N-terminal kinase/planar cell polarity (JNK/PCP) wingless-related (WNT) signaling
JP2002526026A (ja) 表皮ケラチン細胞成長因子の治療目的での使用
Rahman et al. CD13 regulates anchorage and differentiation of the skeletal muscle satellite stem cell population in ischemic injury
Lai et al. VEGF promotes tendon regeneration of aged rats by inhibiting adipogenic differentiation of tendon stem/progenitor cells and promoting vascularization
Bindal et al. Angiogenic effect of platelet-rich concentrates on dental pulp stem cells in inflamed microenvironment
Wang et al. Vascular regeneration in adult mouse cochlea stimulated by VEGF-A165 and driven by NG2-derived cells ex vivo
US10357549B2 (en) Pigment epithelium-derived factor (PEDF) and peptide derivatives thereof for use in osteoblast differentiation and bone growth
JP2020509768A (ja) エネルギー代謝を調節するポリペプチド及びその使用
Ai et al. Retinal blood vessel‐origin yes‐associated protein (YAP) governs astrocytic maturation via leukaemia inhibitory factor (LIF)
CN110721307A (zh) 神经调节蛋白1在制备增强trpc6通道活性产品中的应用
CN114450016B (zh) 生物组织损伤修复剂的制造方法及生物组织损伤修复剂
EP3139944B1 (en) Dsg2-derived short peptide for use in treating ocular angiogenic diseases
Yang et al. Parecoxib prevents nucleus pulposus cells apoptosis by suppressing endoplasmic reticulum stress.
Wu Heterodimer of erythropoietin receptor and β common receptor in renal ischemia-reperfusion injury and repair
Nangle Application of a Novel AAV Gene Therapy: Investigating AAV6. 2-FF in Models of Pulmonary Surfactant-Related Disease
Lee A Novel Role for Abelson Tyrosine-Protein Kinase 2: Characterization of Abl2 in Regulating Myoblast Proliferation and Muscle Fiber Length
WO2024233860A2 (en) Metabolic target for therapy of chronic vascular inflammation
CN118755812A (zh) m6A阅读蛋白IGF2BP1在废用性骨质疏松症诊断和治疗药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180522